Last reviewed · How we verify

NCT05767294

Epidemiological and Clinical Characteristics of Hospitalized Patients Under 5 Years Old With RSV Infection in Central China, Wuhan

ENROLLING BY INVITATION Last updated 22 April 2024
What this trial tests

trial testing Observation in RSV Infection in 10,000 participants. Enrolling by invitation.

Timeline
5 December 2023
Primary endpoint
31 December 2024
1 June 2025

Quick facts

Lead sponsorTongji Hospital
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment10,000
Start date5 December 2023
Primary completion31 December 2024
Estimated completion1 June 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Tongji Hospital

Who can join

Adults 1 Day to 5, any sex, with RSV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will be a multicenter, hospital-based retrospective study. We plan to collect the clinical and laboratory data among all hospitalized ARTI cases in three hospitals in Wuhan from June 1, 2020 to May 31, 2023 and then analyze the epidemiological and clinical characteristics of RSV infection, clarify the gene types of epidemics under 5 years old children after the outbreak in Wuhan, China.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Observation

Trials testing the same drug.

Other recruiting trials for RSV Infection

Currently open trials in the same condition.

Other Tongji Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05767294.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing